Nivolumab + Ipilimumab + Cetuximab/Erbitux + Cisplatin/Platinol + Carboplatin/Paraplatin + Fluorouracil/Adrucil
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Cancer
Conditions
Head and Neck Cancer
Trial Timeline
Oct 5, 2016 → Sep 22, 2022
NCT ID
NCT02741570About Nivolumab + Ipilimumab + Cetuximab/Erbitux + Cisplatin/Platinol + Carboplatin/Paraplatin + Fluorouracil/Adrucil
Nivolumab + Ipilimumab + Cetuximab/Erbitux + Cisplatin/Platinol + Carboplatin/Paraplatin + Fluorouracil/Adrucil is a phase 3 stage product being developed by Ono Pharmaceutical for Head and Neck Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02741570. Target conditions include Head and Neck Cancer.
What happened to similar drugs?
11 of 20 similar drugs in Head and Neck Cancer were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02741570 | Phase 3 | Completed |
Competing Products
20 competing products in Head and Neck Cancer